Commercial Supply Ensitrelvir (S-217622) Intermediates:
S-Ethylisothiourea Hydrobromide CAS 1071-37-0
2,4,5-Trifluorobenzyl Bromide CAS 157911-56-3
Trimethyloxonium Tetrafluoroborate CAS 420-37-1
6-Chloro-2-methyl-2H-indazol-5-amine CAS 1893125-36-4
3-(Chloromethyl)-1-methyl-1H-1,2,4-triazole hydrochloride CAS 135206-76-7
1,3,5-Triazine-2,4(1H,3H)-dione, 3-(1,1-dimethylethyl)-6-(ethylthio)- CAS 1360105-53-8
| Chemical Name | 1,3,5-Triazine-2,4(1H,3H)-dione, 3-(1,1-dimethylethyl)-6-(ethylthio)- |
| Synonyms | 3-tert-butyl-6-(ethylthio)-1,3,5-triazine-2,4(1H,3H)-dione |
| CAS Number | 1360105-53-8 |
| CAT Number | RF-PI1504 |
| Stock Status | In Stock |
| Molecular Formula | C9H15N3O2S |
| Molecular Weight | 229.3 |
| Brand | Ruifu Chemical |
| Item | Specifications |
| Purity | >98.0% |
| Loss on Drying | <1.00% |
| Total Impurities | <2.00% |
| Test Standard | Enterprise Standard |
| Usage | Intermediate of Ensitrelvir (S-217622), COVID-19 |
Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement.
Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture.
3-(Chloromethyl)-1-methyl-1H-1,2,4-triazole hydrochloride (CAS: 135206-76-7) is an intermediate of Ensitrelvir (S-217622). Ensitrelvir is an antiviral drug developed by Shionogi in partnership with Hokkaido University, which acts as an orally active 3C-like protease inhibitor for the treatment of COVID-19 infection. It is taken by mouth, and has been successfully tested against the recently emerged Omicron variant. It became the first Japanese domestic pill to treat COVID-19, third to be regulatorally approved in Japan; in February 2022.